Diabetes Is Still a Risk Factor for Restenosis After Drug-Eluting Stent in Coronary Arteries
- André J. Scheen, MD, PHD1 and
- Fabian Warzée1
- 1Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, Centre Hospitalier Universitaire, Sart Tilman, Liège, Belgium
- Address correspondence to André J. Scheen, Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, Centre Hospitalier Universitaire, Sart Tilman (B35), B-4000 Liège, Belgium. E-mail: andre.scheen{at}chu.ulg.ac.be
We read with interest the meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting (1). This meta-analysis of six clinical trials showed that the odds ratio (OR) of coronary artery restenosis associated with diabetes was 1.61 (95% CI 1.21–2.14, P = 0.004) in univariate logistic regression models, but it decreased to 1.30 (0.99–1.70, P = 0.055) after age was controlled in multivariate models. All trials selected in this meta-analysis used classical bare-metal stents. However, drug-eluting stents (DESs) have been shown to improve outcomes among patients undergoing percutaneous coronary intervention by significantly reducing restenosis rates (2).
We performed …
In this Issue
July 2004, 27(7)
Diabetes Is Still a Risk Factor for Restenosis After Drug-Eluting Stent in Coronary Arteries
